Your gateway to the world of medicine
Cancer News
About Us
Health Professionals
Patients and public
Contact Us

From Chemosensitvity testing in cancer

Cancer Main What's Cancer? Cancer News  

Chemosensitvity testing in cancer

Gregory D. Pawelski

Why should we do Chemosensitvity testing?
When a patient has an infection, doctors often send a sample of infected blood or tissue to a lab where they can grow the bacteria and see which antibiotics are most effective (called Bacterial Culture and Sensitivity Testing). Chemosensitivity testing is an attempt to do something similar for cancer; fresh samples of the patient's tumor from surgery or a biopsy are grown in test tubes and tested with various drugs. Drugs that are most effective in killing the cultured cells are recommended for treatment. It is highly desirable to know what drugs are effective against your particular cancer cells before highly-toxic agents are systemically administered to your body.

One approach to individualizing patient therapy is chemosensitivity testing. Chemosensitivity assay is a laboratory test that determines how effective specific chemotherapy agents are against an individual patient's cancer cells. Often, results are obtained before the patient begins treatment. This kind of testing can assist in individualizing cancer therapy by providing information about the likely response of an individual patient's tumor to proposed therapy. Chemosensitivity testing may have utility at the time of initial therapy, and in instances of severe drug hypersensitivity, failed therapy, recurrent disease, and metastatic disease, by providing assistance in selecting optimal chemotherapy regimens.

All available chemosensitivity assays are able to report drug "resistance" information. Resistance implies that when a patient's cancer cells are exposed to a particular chemotherapy agent in the laboratory, the cancer cells will continue to live and grow. Some chemosensitivity assays also are able to report drug "sensitivity" information. Sensitivity implies that when a patient's cancer cells are treated with a particular chemotherapy agent in the laboratory, that agent will kill the cancer cells or inhibit their proliferation.

The goal of all chemosensitivity tests is to determine the response of a patient's cancer cells to proposed chemotherapy agents. Knowing which chemotherapy agents the patient's cancer cells are resistant to is important. Then, these options can be eliminated, thereby avoiding the toxicity of ineffective agents. In addition, some chemosensitivity assays predict tumor cell sensitivity, or which agent would be most effective. Choosing the most effective agent can help patients to avoid the physical, emotional, and financial costs of failed therapy and experience an increased quality of life.

Fresh samples of the patient's tumor from surgery or a biopsy are grown in test tubes and tested with various drugs. Drugs that are most effective in killing the cultured cells are recommended for treatment. Chemosensitivity testing does have predictive value, especially in predicting what "won't" work. Patients who have been through several chemotherapy regimens and are running out of options might want to consider chemosensitivity testing. It might help you find the best option or save you from fruitless additional treatment. Today, chemosensitivity testing has progressed to the point where it is 85% - 90% effective.

Conventionally, oncologists rely on clinical trials in choosing chemotherapy regimens. But the statistical results of these population-based studies might not apply to an individual. For many cancers, especially after a relapse, more than one standard treatment exists. There is rarely a situation where you would get everyone to agree that there's only one form of therapy. Physicians select drugs based on their personal experience, possible side effects and the patient's condition, among other factors. The system is overloaded with drugs and underloaded with wisdom and expertise for using them.

Chemosensitivity testing might help you find the best option, or save you from fruitless additional treatment. Another situation where chemosensitivity testing might make particularly good sense is in rare cancers where there may not be enough experience or previous ideas of which drugs might be most effective.

Finally, there has been a veritable deluge of new approvals of cytotoxic drugs in recent years as the tortuous FDA process has been speeded and liberalized. In many cases a new drug has been approved on the basis of a single very very narrow indication. But these drugs may have many useful applications - and it's going to take years to find out. Chemosensitivity testing offers a way of seeing if any of these new drugs might apply to your specific cancer.

What is Chemosensitvity testing?
Cell Culture Drug Resistance Testing (CCDRT) or Chemotherapy Sensitivity and Resistance Assays (CSRAs) refers to laboratory testing of a patient's own cancer cells with drugs that may be used to treat the patient's cancer. A group of lab tests known as Human Tumor Assay Systems (HTAS) can aid oncologists in deciding which chemotherapies work best in battling an individual patient's form of cancer. The assay is a lab test performed on a biopsy specimen containing living cancer cells. It's used to determine the sensitivity or resistance of malignant cells to individual chemotherapy agents. Depending on how well the tumor cells respond to each chemotherapy agent, they are rated as sensitive, resistant or intermediate to chemotherapy. The concept is that you are better off using a chemotherapy drug that your tumor reacts to strongly than one your tumor resists.

There have been over 40 publications in peer-reviewed medical literature showing correlations between cell-death assay test results and the results of clinical chemotherapy in more than 2,000 patients. In every single study, patients treated with drugs active in the assays had a higher response rate than the entire group of patients as a whole. In every single study, patients treated with drugs inactive in the assays had lower response rates than the entire group of patients. In every single study, patients treated with active drugs were much more likely to respond than patients treated with inactive drugs, with assay-active drugs being 7 to 9 times more likely to work than assay-inactive drugs. A large number of peer-review publications also reported that patients treated with assay-tested "active" drugs enjoyed significantly longer survival of cancer than patients with assay-tested "negative" drugs.

How can you get tumor or leukemia Tested using chemosensitivity?
Both fluid and solid tumor (200mg or 10mm in size) specimens may be sent out via Federal Express or another overnight courier service for testing at one of more than a dozen labs around the country. Note that the choice of a lab is not a geographical consideration, but a technical consideration. All of the labs that I listed below are experienced and capable of providing very useful information. However, the labs vary considerably with regard to technologies, approach to testing, what they try to achieve with the testing, and cost.

By investing a little time on the phone speaking with the lab directors, you should have enough knowledge to present the concept to the patient's own physician. At that point, the best thing is to ask the physician, as a courtesy to the patient, to speak on the phone with the director of the laboratory in which you are interested, so that everyone (patient, physician, and laboratory director) understand what is being considered, what is the rationale, and what are the data which support what is being considered.

Not all doctors agree on chemosensitivity testing of tumor cells
The fact that some doctors don't agree isn't stopping many cancer patients from taking this matter into their own hands, and sending their live path specimens off to one of the below private labs for assay-testing to be done. In fact, approximately 10,000 individual patient specimens are currently being submitted for testing by more than 1,000 clinical oncologists, surgeons and pathologists annually in the United States. It seems probable that a self-educated oncologist, genuinely on the cutting-edge would tend to be aggressive in actual treatment beyond mere rhetoric and make use of running tests on the biopsy before selecting a chemotherapy option.

In 1983, medical publications introduced assays based on "cell-death" (not cell-growth). This was a good five years before understanding the concept of apoptosis (apoptosis is a genetically programmed cell death pathway which exists in all cells, which is supposed to cause them to commit suicide if they become functionally deranged, but doesn't function properly in cancer cells, allowing them to grow abnormally without committing suicide, which can be triggered to occur by effective anti-cancer drugs).

Because clinical oncologists did not understand apoptosis then, these pioneering publications with "cell-death" (instead of cell growth) endpoints were ignored, and neither clinical trials nor the application of cell death drug resistance assays were supported by academic and private practice clinical oncologists. The clinical utility and clinical accuracy of cell culture drug resistance testing with cell-death endpoints has now been proven.

There has been much discussion about whether assay (in vitro) tests are of any use, as the in vivo response to a drug may very well be different in the body than in the petri dish. But, they said the same for Bacterial Culture and Sensitivity Testing. Doctors cannot remember a time when they didn't have this technology. It is a 'gold' standard. So will Chemosensitivity Testing. After all, cutting-edge techniques can often provide superior results over tried-and-true methods that have been around for many years.

Listing of Specialized Laboratories in the United States:
These labs will provide you and your physician with in depth information and research on the technology they provide. They follow careful quality controlled methods that adhere to College of American Pathologists and Clinical Laboratory Improvement Amendments (CLIA) guidelines.
  • Analytical Biosystems, Inc., Providence, Rhode Island. 1-800-262-6520
  • Anticancer, Inc., San Diego, CA. 1-619-654-2555
  • Cancer Therapeutics, Inc., Thomasville, GA. 1-229-224-6839
  • DiaTech Oncology, Brentwood, TN. 1-615-294-9033
  • Genomic Health, Inc. Redwood City, CA. 1-650-556-9300
  • Genoptix, Inc., San Diego, CA 1-858-523-5000
  • Human Tumor Cloning Laboratory, San Antonio, TX. 1-210-677-3827
  • Impath, Inc., New York, NY. 1-800-447-8881
  • Nu Oncology Labs, Virginia Beach, VA. 1-757-554-0926
  • Oncotech, Inc., Irvine, CA. 1-714-474-9262 / FAX 1-714-474-8147
  • Oncovation LLC, New York, N.Y. 1-212-514-2422
  • Precision Therapeutics, Pittsburgh, PA. 1-866-243-6639
  • Rational Therapeutics Institute, Long Beach, CA. 1-562-989-6455
  • Sylvester Cancer Institute, Miami, FL. 1-305-547-6875
  • Weisenthal Cancer Group, Huntington Beach, CA. 1-866-364-0011
Source: Various Bio-Assay Journals
copyright © 2004-2005 Gregory D. Pawelski all rights reserved

Cancer terms:
Lump: A thickness, bump or growth in any part of the body that can be felt by fingers. Development of a new lump in a patient with cancer is suspicious for reccurrence (return) of cancer. Most lumps that occur in a patient, who did not have cancer in the past, are not cancerous. See cancer terms for more cancer related terms. Chemosensitvity testing in cancer

Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news| Pancreatic cancer news| Prostate cancer news| Endometrial cancer news| General info| What is cancer?| Cancer causes| Is cancer hereditary?| Types of cancer| Cancer statistics| Breast cancer main| Breast cancer symptoms| Colon cancer main| Anal cancer| Bladder cancer main| Lung cancer general| Lung cancer main| Non small cell| Small cell| Ovarian cancer main| Treatment of ovarian cancer| Prostate cancer main| Updates in oncology|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.